JP2021525517A5 - - Google Patents

Info

Publication number
JP2021525517A5
JP2021525517A5 JP2020566612A JP2020566612A JP2021525517A5 JP 2021525517 A5 JP2021525517 A5 JP 2021525517A5 JP 2020566612 A JP2020566612 A JP 2020566612A JP 2020566612 A JP2020566612 A JP 2020566612A JP 2021525517 A5 JP2021525517 A5 JP 2021525517A5
Authority
JP
Japan
Prior art keywords
lymphocytes
peptide
poly
dna molecule
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525517A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/064109 external-priority patent/WO2019229193A1/en
Publication of JP2021525517A publication Critical patent/JP2021525517A/ja
Publication of JP2021525517A5 publication Critical patent/JP2021525517A5/ja
Priority to JP2024034648A priority Critical patent/JP2024063211A/ja
Pending legal-status Critical Current

Links

JP2020566612A 2018-05-30 2019-05-29 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング Pending JP2021525517A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024034648A JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2018/064299 2018-05-30
EP2018064299 2018-05-30
PCT/EP2019/064109 WO2019229193A1 (en) 2018-05-30 2019-05-29 Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034648A Division JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング

Publications (2)

Publication Number Publication Date
JP2021525517A JP2021525517A (ja) 2021-09-27
JP2021525517A5 true JP2021525517A5 (https=) 2022-05-31

Family

ID=62620827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566612A Pending JP2021525517A (ja) 2018-05-30 2019-05-29 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング
JP2024034648A Pending JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024034648A Pending JP2024063211A (ja) 2018-05-30 2024-03-07 内在性活性化誘導シチジンデアミナーゼを利用することによるｂリンパ球のエンジニアリング

Country Status (12)

Country Link
US (1) US20210254106A1 (https=)
EP (1) EP3802841A1 (https=)
JP (2) JP2021525517A (https=)
KR (1) KR20210016446A (https=)
CN (1) CN112384627A (https=)
AU (1) AU2019276261A1 (https=)
BR (1) BR112020024354A2 (https=)
CA (1) CA3100112A1 (https=)
EA (1) EA202092807A1 (https=)
MX (1) MX2020012895A (https=)
SG (1) SG11202011280SA (https=)
WO (1) WO2019229193A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114181901B (zh) * 2021-12-08 2024-02-02 杭州中赢生物医疗科技有限公司 一种免疫细胞的体外诱导扩增和冻存的方法
US20250297288A1 (en) * 2022-05-10 2025-09-25 Editas Medicine, Inc. Genome editing of b cells
WO2024220446A2 (en) * 2023-04-17 2024-10-24 Be Biopharma, Inc. Engineered cell preparations for treatment of hemophilia
CN117063890B (zh) * 2023-07-11 2025-12-05 吉林大学 一种heca基因不表达的异种移植供体猪及制备方法
WO2025147573A2 (en) * 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
DK0841392T3 (da) 1996-11-12 2004-11-22 Pfizer Svækket levende Neospora vaccine
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
AU2002953381A0 (en) * 2002-12-18 2003-01-09 Diatech Pty Ltd In vivo affinity maturation scheme
DK1646715T3 (da) 2003-07-22 2010-08-16 Vivalis Fremstilling af poxvirum med adhærente eller ikke-adhærente fuglecellelinjer
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
EP2638155A1 (en) * 2010-11-08 2013-09-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
US20130102031A1 (en) * 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
EP2927227A4 (en) 2013-01-03 2015-12-30 Celltrion Inc ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2016207402A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
JP2018526007A (ja) * 2015-09-04 2018-09-13 トカジェン インコーポレーテッド ２ａペプチドを含む組換えベクター
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION

Similar Documents

Publication Publication Date Title
JP2021525517A5 (https=)
KR102503130B1 (ko) 내인성 t 세포 수용체의 표적화된 대체
US11591381B2 (en) Gene-edited natural killer cells
AU2018226857B2 (en) Compositions and methods for immunotherapy
CN109844118B (zh) 经操纵的免疫调节因子以及由此改变的免疫力
WO2017070429A1 (en) Methods involving editing polynucleotides that encode t cell receptor
CA3022266A1 (en) Allele editing and applications thereof
JP2023552816A (ja) 細胞内のｍｈｃクラスｉｉを低減する組成物及び方法
IL303970A (en) Compositions and methods for genetically modifying ciita in a cell
AU2019376903A1 (en) Anti-LIV1 immune cell cancer therapy
JP2023501617A (ja) Ｃａｒ－ｔ細胞を製造する方法
US20230014010A1 (en) Engineered cells with improved protection from natural killer cell killing
KR20210092236A (ko) 항-ptk7 면역세포 암 치료법
KR20180018457A (ko) 조작된 면역조절요소 및 이에 의해 변형된 면역 활성
Hudecek et al. Minicircle-based engineering of chimeric antigen receptor (CAR) T cells
WO2021095013A1 (en) Manufacturing process for making t cells expressing chimeric antigen receptors
Arroyo-Olarte et al. Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer: R. Arroyo-Olarte et al.
JP2025525437A (ja) 操作されたｔ細胞
US20250034558A1 (en) Compositions and methods for targeting, editing or modifying human genes
US20260071238A1 (en) Materials and processes for engineering hypoimmunogenicity
US20250197811A1 (en) Compositions and methods for generating cells with reduced immunogenicity
WO2023233342A2 (en) Gene-edited natural killer cells
US20260071189A1 (en) Biomaterials and processes for immune synapse modulation of hypoimmunogenicity
EP4705456A1 (en) Compositions and methods for targeting, editing or modifying human genes
AU2024233625A1 (en) Systems targeting psma and ca9